John Newman
Stock Analyst at Canaccord Genuity
(2.24)
# 2,727
Out of 5,124 analysts
90
Total ratings
44.3%
Success rate
-2.14%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 → $25 | $18.09 | +38.20% | 6 | Dec 19, 2025 | |
| ACLX Arcellx | Maintains: Buy | $130 | $65.20 | +99.39% | 10 | Dec 8, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 → $1,057 | $771.87 | +36.94% | 20 | Dec 4, 2025 | |
| CMPX Compass Therapeutics | Initiates: Buy | $10 | $5.37 | +86.22% | 1 | Dec 3, 2025 | |
| NUVL Nuvalent | Initiates: Buy | $126 | $100.59 | +25.26% | 1 | Nov 12, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $10.10 | +107.92% | 2 | Oct 21, 2025 | |
| MRUS Merus | Downgrades: Hold | $67 → $97 | $90.00 | +7.78% | 3 | Sep 30, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $14.85 | +48.15% | 10 | Sep 24, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.37 | +921.90% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $95.20 | +80.08% | 8 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.49 | +436.91% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $25 | $5.65 | +342.48% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $304 → $128 | $8.42 | +1,420.19% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $7.21 | +496.39% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.87 | +472.08% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $27.22 | +61.65% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $13.33 | +185.07% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.18 | +421.24% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $15.95 | - | 1 | Sep 13, 2017 |
Atara Biotherapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $18.09
Upside: +38.20%
Arcellx
Dec 8, 2025
Maintains: Buy
Price Target: $130
Current: $65.20
Upside: +99.39%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $771.87
Upside: +36.94%
Compass Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $5.37
Upside: +86.22%
Nuvalent
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $100.59
Upside: +25.26%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $10.10
Upside: +107.92%
Merus
Sep 30, 2025
Downgrades: Hold
Price Target: $67 → $97
Current: $90.00
Upside: +7.78%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $14.85
Upside: +48.15%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.37
Upside: +921.90%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $95.20
Upside: +80.08%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.49
Upside: +436.91%
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.65
Upside: +342.48%
Sep 11, 2024
Maintains: Buy
Price Target: $304 → $128
Current: $8.42
Upside: +1,420.19%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $7.21
Upside: +496.39%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.87
Upside: +472.08%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $27.22
Upside: +61.65%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $13.33
Upside: +185.07%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.18
Upside: +421.24%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $15.95
Upside: -